Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
The prevalence of serum LATS and LATS-P in untreated Graves' disease has been studied in eighty-three patients with thyroid overactivity; twelve (14%) were found to have significant levels of LATs and LATS-P whilst fifty-nine (72%) had significant levels of LATS-P alone. Twelve (14%) had neither activity. There was a very wide range in both activities. LATS was invariably found in association with a significantly greater concentration of LATS-P. There was no correlation between LATS-P and thyroid mass, as estimated from scintiscanning, thyroidal radioiodine uptake at 4 and 48 h, total serum T4 and total serum T3. Neither LATS nor LATS-P were detected in eleven patients with toxic multinodular goitre nor four with solitary toxic adenoma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006044:Goiter, Nodular / Q000276:immunology; D006111:Graves Disease / Q000276:immunology; D006801:Humans; D006980:Hyperthyroidism / Q000276:immunology*; D007074:Immunoglobulin G / Q000032:analysis*; D008135:Long-Acting Thyroid Stimulator / Q000032:analysis*; D008297:Male; D008875:Middle Aged
D007074:Immunoglobulin G; D008135:Long-Acting Thyroid Stimulator